Site search icon.
Mobile navigation icon.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.


Hereditary angioedema (HAE) is a rare genetic disease that causes recurrent, debilitating, and potentially life-threatening attacks of angioedema in the body. HAE affects about 1 in 50,000 people of all ages.2,3

An accurate and early diagnosis is an important first step in developing an effective management plan for your patients with HAE. Untreated HAE attacks can grow in intensity and may take longer to resolve.3-5

HAE laryngeal attacks can be life-threatening, and they are especially dangerous for children who lack the ability to self-administer treatment during an attack or who may be unable to describe their symptoms.4,5

TAKHZYRO is not indicated for acute treatment.

For both adult and pediatric patients, attacks can occur in the…4

Image of adult and child body figures, indicating areas mostly commonly affected by HAE attacks: face, larynx, abdomen, genitals, hands, and feet.

The frequency and severity of HAE attacks may
vary for each individual over time regardless of
age, meaning that past attacks do not predict
the severity of future attacks.7

To help keep track of changes in HAE attacks,
use this Hereditary Angioedema (HAE)
Assessment Questionnaire for Patients.


Since most attacks are unpredictable and not prompted by triggers, the 2021 international WAO/EAACI guidelines suggest physicians should not support excessive avoidance of suspected triggers, which can limit a patient's normal life.8

  • High HAE disease activity often comes with impact on daily life8
  • The daily lives of some patients with low attack rates are also impacted, thought to be linked to the unpredictability and continuous fear of HAE attacks8

EAACI=European Academy of Allergy and Clinical Immunology; WAO=World Allergy Organization.

My HAE was so bad [that] I had a hard time making my plans with my family... I decided I wanted a medication that would help prevent attacks before they happened.
SorayaReal TAKHZYRO patientSearching for a treatment with proven results in a number of people.

Ask yourself the following questions to help understand the signs of a patient who is trigger avoidant with a low attack history

  • Does your patient experience HAE swells in their extremities, but not classify them as attacks?
  • Does your patient avoid activities because of their HAE?
  • Would your patient live their life differently if they were on a preventive treatment?

Explore A Patient Profile

Visual representation of TAKHZYRO®, a monoclonal antibody.

TAKHZYRO is plasma-free
and inhibits plasma
kallikrein activity9

Find out how it works

Long-term HAE prevention
should be individualized
and considered in all
patients with HAE8


Reference: 1. Banerji A, Bernstein JA, Johnston DT, et al. Allergy. 2022;77:979–990. 2. Busse PJ, Christiansen SC, Riedl MA, et al. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046 3. Banerji A. Ann Allergy Asthma Immunol. 2013;111(5):329-336. doi:10.1016/j.jaip.2020.08.046 4. Zuraw BL. N Engl J Med. 2008;359(10):1027-1036. doi:10.1056/NEJMcp0803977 5. MacGinnitie AJ. Pediatr Allergy Immunol. 2014;25(5):420-427. doi:10.1111/pai.12168 6. Johnston DT, Smith RC. Allergy Asthma Proc. 2020;41(6)(suppl 1):S43-S46. doi:10.2500/aap.2020.41.200042 7. Bork K, Davis-Lorton M. Eur Ann Allergy Clin Immunol. 2013;45(1):7-16. 8. Maurer M, Magerl M, Betschel S, et al. Allergy. 2022;77(7):1961-1990. doi:10.1111/all.15214 9. Takhzyro. Prescribing information. Dyax Corp; 2023.